Background
==========

After reactivation from latency in facial nerve ganglia, herpes simplex virus type-1 (HSV-1) may cause tracheobronchitis or pneumonitis featuring life-threatening respiratory-failure with bilateral changes on thoracic imaging \[[@B1]-[@B4]\]. HSV-1 pneumonitis is comparatively well investigated in critically ill patients under mechanical ventilation, where \~90% show an oropharyngeal reactivation of the virus within the first 10 days \[[@B5]\]. In a number of retro- and prospective studies in this setting presence of cytology-proven HSV-1 pneumonitis was shown to have a poorer outcome, but antiviral treatment was not beneficial \[[@B6]-[@B9]\]. Immunosuppressed patients with malignancies, organ transplants, and cytotoxic treatments for various reasons are the other large, though extremely heterogeneous, group of patients that have been described to develop HSV-1 pneumonitis. Data on the disease in these subjects is more scarce and mainly consists of anecdotal accounts \[[@B10]-[@B16]\]. Only one retrospective study of bronchoalveolar lavage (BAL) microbiology/virology results from renal transplant patients is available and, very recently, a retrospective study on HSV-1 pneumonitis in patients with solid tumors was published representing the first systematic approaches in the field \[[@B17],[@B18]\]. In view of lack of data, it was the goal of the present study to investigate the potential significance of HSV-1 pneumonitis in patients under a maintenance regimen of ambulatory immunosuppression. We therefore retrospectively analyzed admissions for pneumonia/pneumonitis in a comparatively large cohort of outpatients with rheumatoid, vasculitic and connective tissue autoimmune disease over a period of 8 years.

Methods
=======

This retrospective study was approved by the local Ethics Committee. The local electronic database containing all patient diagnoses and discharge summaries of our rheumatologic outpatient clinic and the affiliated hospitals of the Department of internal medicine were searched for a combination of the terms of the rheumatologic/vasculitic/connective tissue disease and pneumonia or pneumonitis. Each episode of a positive hit was reviewed. Severity of current immunosuppressive treatment was scored 0--4 as follows: 0 = no immunosuppressive medication; 1 = low-dose: (prednisone ≤ 10 mg/d) or (azulfidine/chloroquine); 2 = intermediate: (prednisone 20--40 mg/d) or (prednisone 10 mg/d+methotrexate) or (prednisone 10 mg/d+leflunomide) or (cyclosporine) or (prednisone+mycophenolate mofetil) or (prednisone 20 mg/d+azathioprine); 3 = strong: (prednisone 40 mg/d+methotrexate) or (prednisone 20 mg/d+methotrexate+anakinra) or (prednisone 20 mg/d+methotrexate+leflunomide) or (prednisone 20 mg/d+etanercept) or (prednisone 40 mg/d+azathioprine) or (lower dose prednisone+azathioprine+leukopenia); 4 = maximal: (prednisone 60 mg/d+cyclophosphamide) or (prednisone 100 mg/d).

At the time of in-hospital treatment the patients were diagnosed and treated by current standards of clinical practice and were not part of a prospective clinical trial regarding the treatment of pneumonia or pneumonitis.

Fiberoptic bronchoscopy (FOB) was performed when deemed appropriate. Bronchoalveolar lavage (BAL) was performed with each bronchoscopic examination and material was subsequently centrifuged, fixated in 4% paraformaldehyde and stained using hematin-eosin. Standard microscopic examination was performed. BAL fluids were also subjected to viral polymerase chain reaction (PCR) when deemed appropriate that always consisted of testing for HSV-1 and CMV (cytomegaly virus). In selected positive cases immunohistochemistry of BAL for HSV-1 was performed using a rabbit polyclonal antibody against HSV-1 (DAKO Laboratories, Denmark). Bronchoscopic biopsies were performed when deemed appropriate and processed using standard protocols. Microbiologic and serologic diagnostics were performed using standard protocols.

Statistical analysis was performed using Prism 4 software (Graph Pad, La Jolla, CA).

Results
=======

As it is unclear to which extent an outpatient regimen of current standard immunosuppression for autoimmune disease may confer a risk for HSV-1 pneumonitis, we retrospectively reviewed the charts of \~1400 patients with rheumatoid arthritis (\~1000), ANCA-associated vasculitis (\~80), and systemic lupus erythematosus (SLE) (\~320) that were followed during the years 2000--2007 in the nephrology and rheumatology outpatient clinic at the Medical Policlinic, LMU University of Munich. During the study period 766 ward-admissions of patients with rheumatologic/vasculitic/connective tissue autoimmune disease occurred. Among those there were 63 (8%) episodes of admission from 63 outpatients of our clinic presenting with respiratory deterioration that were ultimately diagnosed to be due to pneumonia or pneumonitis (Table [1](#T1){ref-type="table"}). As a rough estimate one can infer an incidence of community-acquired respiratory infection or pneumonitis requiring hospitalization in outpatients with autoimmune disease of \[63 patients \* 100/(1400 patients \*8 years)\], i.e., \~0.5% per year.

###### 

Classification and clinical course of the study population, i.e., 63 patients with rheumatic/vasculitic or connective tissue disease admitted to hospital and diagnosed to have pneumonia/pneumonitis

                                           **Total admissions to hospital**   **Admissions for PNA (% of admissions)**   **FOB with BAL in PNA (% of PNA)**   **BAL-PCR for HSV-1 and CMV (% of FOB)**   **Positive HSV-1 BAL-PCR (% of PNA)**   **Requirement of intubation in PNA (% of PNA)**   **Mean and (median) age of patients with PNA in ys**   **Mean immuno-suppression severity score of patients with PNA\***   **Lethal outcome in PNA**
  ---------------------------------------- ---------------------------------- ------------------------------------------ ------------------------------------ ------------------------------------------ --------------------------------------- ------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------- ---------------------------
  **Wegener\'s Granulomatosis**            74                                 13 (18%)                                   4                                    4                                          2 (cases 3, 5)                          2                                                 66 (68)                                                3.3                                                                 2
  **Rheumatoid arthritis**                 515                                34 (7%)                                    12                                   6                                          2 (cases 1,4)                           5                                                 71 (74)                                                1.5                                                                 3
                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Polyangiits**                          22                                 4 (18%)                                    3                                    1                                          1 (case 2)                              0                                                 63 (64)                                                3.5                                                                 0
  **Systemic lupus erythematosus (SLE)**   155                                12 (8%)                                    4                                    3                                          1 (case 6)                              1                                                 53 (58)                                                1.6                                                                 1
                                                                                                                                                                                                                                                                                                                                                                                                                              
  **total**                                **766**                            **63 (8%)**                                **23 (37%)**                         **14 (61%)**                               **6 (10%)**                             **8 (12%)**                                       **66 (66)**                                            **2.0**                                                             **6 (10%)**

Absolute numbers or percentages are given, (\*) based on 56 of the 63 cases where information on immunosuppressive regimens was reliably available. In order to estimate the degree of immunosuppressive strength in the patient population, an arbitrary score ranging form 0--4 was applied (see methods). Abbreviations: BAL = bronchoalveolar lavage, FOB = fiberoptic bronchoscopy, PNA = pneumonia/pneumonitis, ys = years.

In 23 of these 63 patients bronchoscopy with lavage was performed for diagnostic purposes within the first four days of admission, which in 14 (61%) also comprised PCR analysis for HSV-1. Thereby a total of six patients (10% of admissions for pneumonia) with positive HSV-1 DNA detection in alveolar fluids was identified. In order to estimate the degree of immunosuppressive strength in the patient population, an arbitrary score ranging form 0--4 was applied (see methods).

Relevant clinical, imaging and laboratory data on the six patients with a positive HSV-1 DNA detection on BAL are summarized in Table [2](#T2){ref-type="table"}.

###### 

Synopsis of patient data on all cases with a positive HSV-1 result on PCR of bronchoalveolar lavage

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Clinical data**                                                               **Case 1**                                                         **Case 2**                               **Case 3**                                                 **Case 4**                                                                                                    **Case 5**                                                                                                      **Case 6**
  ------------------------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age at presentation (yrs), gender                                               74, f                                                              74, m                                    60, m                                                      67, m                                                                                                         72, m                                                                                                           65, f

  Rheumatological diagnosis (duration in years)                                   Rheumatoid arthritis, seronegative\                                pulmonary microscopic Polyangiitis\      Wegener\'s Granulomatosis\                                 Rheumatoid arthritis, seropositive\                                                                           Wegener\'s Granulomatosis\                                                                                      Systemic lupus erythematosus\
                                                                                  8                                                                  3                                        2                                                          10                                                                                                            8                                                                                                               4

  Co-Morbidities                                                                  allergic asthma                                                                                             renal insufficiency                                        diabetes, septic arthritis                                                                                    HHT, renal insufficiency                                                                                        

  Immunosuppression (severity score)                                              Pred 20 mg/d + MTX 15 mg/w + Lefl 20 mg/d (3)                      Pred 50 mg/d + Cyclo 150 mg/d p.o.\      Pred 20 mg/d +Cyclo 150 mg/d\                              Pred 20 mg/d + MTX 7.5 mg/w + Anakinra 100 mg/d (3)                                                           Pred 40 mg/d + Cyclo 500 mg/m i.v.\                                                                             Pred 20 mg/d + Aza 150 mg/d, pancytopenia\
                                                                                                                                                     (4)                                      (4)                                                                                                                                                                      (4)                                                                                                             (3)

  clinical presentation in the outpatient setting prior to admission              21 days of cough, fever                                            3 days of bloody cough, dysphagia        3 days of dyspnea, syncope                                 7 days of dyspnea, cough                                                                                      5 days of dyspnea, cough, weakness                                                                              1 day of dyspnea, non-productive cough

  Notable findings                                                                HSV-1 positive oral lesion                                         none                                     HSV-1 positive oral lesion                                 none                                                                                                          HSV-1 positive nasal lesion                                                                                     none

  Ventilatory support required                                                    CPAP                                                               no                                       intubation                                                 intubation                                                                                                    no                                                                                                              no

  **Radiological findings**                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Chest-XR                                                                        diffuse bilateral ground-glass opacities                           interstitial pattern                     interstitial pattern                                       bilateral bronchopneumonic infiltrates with pleural effusions                                                 bilateral bronchopneumonic infiltrates                                                                          unilateral infiltrate

  High-resolution CT-scan                                                         diffuse bilateral ground-glass opacities                           right-sided diffuse pleural effusions    diffuse bilateral ground-glass opacities (no granulomas)   extensive bilateral bronchopneumonic infiltrates with pleural effusions, atelectasis, hilar lymphadenopathy   diffuse bilateral granulomas                                                                                    unilateral bronchopneumonic infiltrate

  **Bronchoscopy/pathology**                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  performed on hospital day                                                       2                                                                  2                                        2                                                          2                                                                                                             2                                                                                                               4

  Macroscopic mucosal aspect                                                      Vulnerable, inflammamation                                         normal                                   inflammation                                               acute bronchitis                                                                                              vulnerable, acute bronchitis                                                                                    vulnerable

  BAL cytology: inclusion bodies                                                  Positive                                                           positive                                 positive                                                   n.a.                                                                                                          n.a.                                                                                                            n.a.

  Lung biopsy                                                                     Non-specific (chronic) bronchitis                                  n.p.                                     non-specific fibroelastosis                                n.p.                                                                                                          n.p.                                                                                                            n.p.

  HSV-1 immunohistology of BAL cytology or of lung biopsy                         n.p.                                                               positive                                 n.p.                                                       n.p.                                                                                                          n.p.                                                                                                            n.p.

  **Relevant identified infectious agents of pneumonia/pneumonitis (from BAL)**   **HSV-1 as sole agent**                                            **HSV-1 as sole agent**                  Aspergillus, K. pneumoniae, HSV-1                          MRSA, P. aeruginosa, K. pneumoniae, HSV-1                                                                     S. aureus, P. aeruginosa, Influenza A, HSV-1                                                                    S. aureus (coag neg), P. aeruginosa, Enterococci, HSV-1, M. kansasii

  **Treatment**                                                                   \- day 1: ceftriax+ery (for 7 days; overlap with acyclo 5 days)\   \- day 1: moxi (for 2 days)\             \- day 1: mero + ery + fluc\                               sequential:\                                                                                                  sequential:\                                                                                                    sequential:\
                                                                                  - day 2: acyclo                                                    - day 2: swap to acyclo monotherapy      - day 2: add acyclo + amphoB for fluc\                     - ceftr+moxi\                                                                                                 - metro+clari +ceftriax\                                                                                        - clari+cipro+ceftaz\
                                                                                                                                                                                              - later: add cipro+ tobra + vanco for mero                 - genta+tazo+fluc\                                                                                            - day 3 ceftaz for ceftriax                                                                                     - fluc (for 14 days)\
                                                                                                                                                                                                                                                         - mero\                                                                                                                                                                                                                       from day 14: INH+ rifampicin+ethambutol
                                                                                                                                                                                                                                                         - vanc+linez\                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                         from day 2: acyclo                                                                                                                                                                                                            

  **Outcome**                                                                     recovery after 7 days                                              recovery after 11 days                   lethal after 28 days (ARDS)                                lethal after 33 days (ARDS)                                                                                   Initial recovery after 28 days, but lethal after 110 days (ARDS) with persistant high HSV-1 viral load on BAL   recovery after 38 days

  **Our Diagnosis/comment**                                                       most likely isolated HSV-1 pneumonitis                             most likely isolated HSV-1 pneumonitis   Bacterial, fungal and HSV-1 pneumonia/pneumonits           Bacterial bronchopneumonia with HSV-1 reactivation                                                            Bacterial pneumonia with untreated HSV-1 reactivation. A second BAL PCR showed an increasing viral load         Mycobacteriosis due to M. kansasii (responsive to treatment). HSV-1 reactivation without radiographic signs of pneumonitis that was not treated antivirally.

  **Complete microbiological work-up**                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Blood cultures                                                                  negative                                                           negative                                 negative                                                   negative                                                                                                      negative                                                                                                        negative

  Mycobacteria culture/PCR BAL                                                    negative                                                           negative                                 negative                                                   negative                                                                                                      negative                                                                                                        **positive**(M. kansasii)

  Aspergillus                                                                     negative                                                           negative                                 **positive**(serum Ag & culture)                           negative                                                                                                      n.p.                                                                                                            negative (serum AG)

  P. jirovecii BAL                                                                negative                                                           negative                                 negative                                                   negative                                                                                                      negative                                                                                                        negative

  MRSA culture Sputum                                                             negative                                                           negative                                 negative                                                   **positive**                                                                                                  negative                                                                                                        negative

  P. aeruginosa culture BAL                                                       negative                                                           negative                                 negative                                                   **positive**                                                                                                  **positive**                                                                                                    **positive**

  K. pneumoniae culture BAL                                                       negative                                                           negative                                 **positive**                                               **positive**                                                                                                  negative                                                                                                        negative

  M. pneumoniae                                                                   negative (PCR BAL)                                                 negative (serology)                      negative (serology)                                        negative (PCR BAL)                                                                                            negative (PCR BAL)                                                                                              n.p.

  C. trachomatis/pneumoniae                                                       negative (serology)                                                n.p.                                     negative (PCR BAL)                                         negative (PCR BAL)                                                                                            negative (PCR BAL)                                                                                              negative (PCR BAL)

  Legionella-Ag (Urine)                                                           negative                                                           negative                                 negative                                                   negative                                                                                                      negative                                                                                                        n.p.

  Complete virological work-up                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  HSV-1 PCR BAL, Geq/ml                                                           9.750.000                                                          284.000                                  700.000                                                    850.000                                                                                                       10.250.000                                                                                                      310.000

  CMV-PCR BAL                                                                     negative                                                           Negative                                 negative                                                   negative                                                                                                      negative                                                                                                        negative

  Influenza A PCR BAL\* (season of presentation)                                  n.p. (May)                                                         n.p. (April)                             negative (January)                                         n.p. (September)                                                                                              **positive**(February)                                                                                          n.p. (June)

  Adenovirus PCR BAL\*\*                                                          Negative                                                           negative                                 negative                                                   n.p.                                                                                                          n.p.                                                                                                            n.p.

  HIV-1/2-Ag ELISA                                                                n.p.                                                               n.p.                                     negative                                                   n.p.                                                                                                          Negative                                                                                                        n.p.
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations used are: acyclo = acyclovir, Ag = antigen, amphoB = amphotericin B, ARDS = adult respiratory distress syndrome, Aza = azathioprine, BAL = bronchoalveolar lavage, ceftaz = ceftazidime, ceftriax = ceftriaxone, cipro = ciprofloxacin, clari = clarithromycin, CPAP = continuous positive airway pressure, CT = computed tomography, coag neg = coagulase negative, cyclo = cyclophosphamide, d = day, ery = erythromycin, fluc = fluconazole, genta = gentamycin, Geq/ml = genome equivalents/ml; HHT = hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome), INH = isoniazid, Lefl = leflunomide, linez = linezolid, mero = meropenem, metro = metronidazole, moxi = moxifloxacin, MTX = methotrexate, Pred = prednisone, tazo = piperacillin/tazobactam, tobra = tobramycin, vanco = vancomycin, w = week. \*testing was seasonal during winter only. \*\*testing was at the discretion of the physician performing bronchoscopy.

Two cases (Case 1 and 2) in which no other viral, bacterial or fungal agent than HSV-1 on BAL PCR was found and in which imaging studies were suggestive for HSV-1 pneumonitis were successfully treated with acyclovir leading to rapid clinical improvement. In both cases, the initial chest radiograph and thoracic CT showed diffuse infiltrations or ground glass opacities. Representative images are shown in Figure [1A, B](#F1){ref-type="fig"}. HSV-1 infection may feature a macroscopically vulnerable aspect of the bronchial mucosa as a non-specific sign (Figure [1C](#F1){ref-type="fig"}). In order to increase diagnostic certainty in Case 2, immunohistochemical staining of bronchioalveolar cells for HSV-1 was performed, which proved positive (Figure [2](#F2){ref-type="fig"}). In both cases inclusion bodies of epithelial cells from BAL were present. Our diagnosis in Case 1 and 2 was isolated HSV-1 pneumonitis, which was supported by the response to acyclovir in the absence of prolonged antibacterial treatment.

![**Imaging study from Case 1**. A: Conventional chest radiograph with diffuse interstital pattern. B: High-resolution-CT (HRCT) featuring small pleural effusions and partial atelectasis of the right lower lobe in addition to distinctive ground-glass opacities. C: Fiberoptic bronchoscopy image showing a vulnerable tracheobronchial mucosa with multiple spontaneous bleeding stigmata, consistent with generalized tracheobronchial inflammation.](1471-2466-9-22-1){#F1}

![**Immunohistochemical staining for HSV-1 in a fixated cyotspun obtained from BAL from Case 2 identifying a positive cell (dark brown colour)**. Bottom and left: alveolar macrophages and lymphocytes with degenerative changes.](1471-2466-9-22-2){#F2}

Case 3 and 4 displayed an initial co-infection with fungal or bacterial agents and HSV-1 and required prolonged mechanical ventilation. Imaging studies were compatible with viral pneumonitis, but in Case 4 infiltrates suggesting bronchopneumonia were also clearly present. The mucosa was macroscopically inflamed in both cases. While Case 3 had inclusion bodies on cytology, such studies were not pursued in Case 4 due to obvious bronchopneumonia. Both patients had a fatal outcome after a prolonged in-hospital stay despite adequate antiinfective treatment that included timely administration of acyclovir.

Cases 5 and 6 are different from the former four cases therein that no bilateral groundglass opacities were present on thoracic CT and no antiviral treatment was initiated. In Case 5, a high HSV-1 viral load from BAL fluids was ignored given the detection of Influenza A virus with S. aureus and Ps. aeruginosa. The patient improved on antibacterial treatment alone and was discharged. He was readmitted one month later with *de-novo*respiratory deterioration that resulted in the need for intubation after the administration of a series of antimicrobial courses that always excluded acyclovir. CT and a second BAL now showed ground glass opacities/ARDS and an even higher HSV-1 viral load. The patient died from ARDS before antiviral treatment could be initiated. Case 6 featured an unilateral bronchopneumonic infiltrate and was treated with standard antibacterial regimens until *Mycobacterium kansasii*grew from the initial BAL. Treatment was changed accordingly and the patient recovered without the administration of antivirals.

In an area of controversy, the first two cases provide further evidence that in selected patients, if ascertained to be the sole agent, HSV-1 is a relevant pathogen of pneumonitis that is amenable to treatment. Cases 3--6 reflect the great difficulty of dissecting the role of HSV-1 in infections with multiple pathogens \[[@B19]\] and illustrate that HSV-1 pneumonitis is a diagnosis of exclusion requiring a complete microbiological workup. It remains speculative if timely suppression of HSV-1 viral loads by antiviral treatment in Case 5 would have altered the patient\'s course.

In the present study of 63 patients with autoimmune disease and pneumonia/pneumontis, no offending agent could be found in 60% of cases. In the remaining 40% a broad spectrum of bacteria, fungi and viruses was identified (Figure [3A](#F3){ref-type="fig"}). Of note, one case of pneumonitis was due to methotrexate. Two cases (3.2%) were most likely due to HSV-1, while HSV-1 was a bystander of other agents in the remaining four cases.

![**A: Detected primary responsible (leading) infectious agents in 63 patients with ambulatory-acquired pneumonia/pneumonitis and autoimmune disease**. RSV = respiratoy syncytial virus. B: Immunosuppression scores were significantly more severe in the 6 patients with HSV-1 detection in BAL than in those subjects without clinical or laboratory evidence for HSV-1 (as assessed for 56/63 patients with reliable information on immunosuppressive regimens available; \*\* p \< 0.01, Mann-Whitney two-sided test).](1471-2466-9-22-3){#F3}

When comparing the six HSV-1-positive cases to those where HSV-1 was neither detected nor suspected with respect to the severity of immunosuppression, a significantly higher degree of immunosuppression in the HSV-1-positive group was noted (p \< 0.01, two-sided Mann-Whitney analysis) (Figure [3B](#F3){ref-type="fig"}). This analysis was performed including 56 of the 63 patients where reliable information on maintenance immunosuppression was available. In order to exclude selection bias, the comparison was also performed using the subgroup of 8 patients that were proven to be HSV-1 negative by BAL. Albeit not reaching the same level of significance, a similar trend was observed with a similar median immunosuppression severity score of 2.0 in the HSV-1 negative group (data not shown). Though great caution must be applied in interpreting small numbers, it is intriguing that patients with Wegener\'s Granulomatosis and vasculitis, who had the strongest immunosuppression (score 3.3--3.5) also had a HSV-1 positive BAL more often (15--25% of pneumonia/pneumonitis) than Rheumatoid arthritis and SLE patients (6--8% of pneumonia/pneumonitis) who were also on a milder immunosuppressive regimen (score 1.5--1.6) (Table [1](#T1){ref-type="table"}).

Discussion
==========

Patients with systemic autoimmune disease have an alteration of immune responses that is due to both the action of immunosuppressive treatment and to the underlying condition itself \[[@B20],[@B21]\]. They are at increased risk for developing opportunistic infections among which respiratory tract involvement is associated with potentially adverse outcomes. Clinical workup of respiratory deterioration in this setting is complicated by the fact that not only bacterial, fungal or viral infectious agents but also a pulmonary flare of the systemic disease or drug-related pulmonary toxicity must be taken into the differential diagnosis. Indicators that raise suspicion for HSV-1 pneumonitis in immunocompromised patients are severe respiratory insufficiency combined with pathologic findings on imaging studies. Thoracic radiographs show segmental bilateral opacities (\~95%) and pleural effusions (\~50%) while CT may show ground-glass opacities (\~100%), focal consolidations (\~75%), and pleural effusions (\~88%) \[[@B22],[@B23]\]. Especially ground-glass opacities are a useful diagnostic hint in the immunocompromised, suggesting either an opportunistic infection due to Pneumocystis jirovecii, CMV, HSV-1, or other viruses \[[@B24]\]. Other non-infectious differential diagnoses of ground glass opacities have been reviewed by \[[@B24]\].

HSV-1 pneumonitis is a diagnosis of exclusion relying on clinical plausibility, positive viral testing, and imaging studies. The definition of clinically relevant positive viral testing is a matter of controversy. A recent study in patients under prolonged mechanical ventilation by Luyt *et al*. required the combination of (i) clinical deterioration, (ii) HSV-1 detection in the lower respiratory tract by either PCR or culture, and (iii) cytological or histological evidence of inclusion bodies from either BAL fluids or biopsies to specifically define HSV-1 pneumonitis \[[@B9]\]. While viral cultures are difficult to handle, PCR of BAL fluids has become the most popular diagnostic tool since it is easily performed and sports a high sensitivity. Specificity however, may be lacking due to potential contamination with fluids from oropharyngeal reactivation, which may even occur in plain bacterial pneumonia \[[@B5],[@B9],[@B19],[@B25]\]. Indeed, in Luyt\'s study, only 43% of those with a positive PCR result also had cytological/histological evidence of infection. Conversely, these cytological/histological criteria lack sensitivity as illustrated by the fact that even open lung biopsies may be negative in the case of autopsy-proven HSV-1 pneumonitis \[[@B4]\]. From a theoretical point of view, HSV-1 viraemia could be an additional specific diagnostic tool, which is, again, associated with a marked reduction in sensitivity \[[@B9]\].

A careful microbiological and remaining virological workup is necessary to define by exclusion isolated HSV-1 pneumonitis. Unfortunately, results of bacterial sampling are often falsely negative, be it due to inadequately low amounts material, assay insensitivity or prior antibiotic use, to name just a few. This is also illustrated by the 60% of cases of pneumonia in our study in which no offending agent was detected despite clinical evidence of infection. Hence, the possibility of falsely negative bacterial testing also applies as a *caveat*to our Cases 1 and 2. Our centre performed viral testing of BAL fluids for influenza routinely during winter. Concerning other viruses such as adenovirus and coronavirus each centre should define a standard in order to avoid omission or over-testing.

Viral load of BAL fluids detected by PCR correlates positively with the presence of cytology/histology-proven HSV-1 pneumonitis and negatively with outcome \[[@B6],[@B9],[@B16]\], but is not necessarily helpful in establishing the diagnosis due to potentially great variations in sampling conditions. However, it is intriguing that Case 1 in our series who was on treatment with leflunomide showed a viral load (9.750.000 Geq/ml) that was 3 and 13-fold greater than the detected average (3.700.000) and median (775.000) of all cases, respectively, while the clinical course was prolonged (21 days prior to admission to hospital) and comparatively mild. Leflunomide exhibits antiviral effects against HSV-1 by inhibiting the assembly of viral capsids but not DNA-replication at dosages used in rheumatic patients \[[@B26]\]. It is tempting to speculate, that leflunomide might have led to the shedding of ill-assembled virions in Case 1.

As outlined in the introduction, studies on HSV-1 pneumonitis in patients with various immunosuppressive conditions are just beginning to emerge \[[@B27]\]. The present study retrospectively analyzed admissions for pneumonia/pneumonitis in a comparatively large cohort of outpatients with autoimmune disease under a maintenance regimen of immunosuppression. Although the considerable limitations of a retrospective design must be borne in mind, the data provide some perspective on the frequency of HSV-1 and other bacterial, fungal and viral agents leading to pulmonary infection in this patient group.

Conclusion
==========

Respiratory deterioration and pneumonia leading to hospital admission was a common event in outpatients with autoimmune diseases treated with current standard immunosuppressive regimens. Acute life-threatening respiratory failure associated with the detection of HSV-1 in the lower respiratory tract was a rare, but significant finding. Based on our findings, diagnostic virological workup in this particular patient cohort should include HSV-1 before starting, but without delaying treatment. In an area of controversy \[[@B19],[@B28]\], we provide further evidence that immunocompromised patients may develop a condition that is most accurately described as HSV-1 pneumonitis and that appears amenable to treatment.
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